HMHendrik A. Messal

Hendrik A. Messal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hendrik A. Messal has a total of 186 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Watching cancer begin: emerging tools to visualize the first steps of tumorigenesis

    by Hendrik A. Messal, Larissa Mourao, Lea Dörner, Colinda L.G.J. Scheele, Jacco van Rheenen


  • Open Access

    Beyond the chaos: How architecture structures tumour biology

    by Lea Dörner, Catrin Lutz, Stefan Prekovic, Hendrik A. Messal

    Cancer is increasingly recognised as a complex and heterogeneous disease, shaped not only by genetic mutations but also by the physical and biochemical context in which tumours develop. The spatial position of a cell, including its physical, cellular and molecular surroundings, shapes its fate, phenotypic plasticity and potential to transform and drive tumour progression and evolution. Tissue architecture provides a powerful framework for understanding the complex dynamics of cancer. It integrates the structural organisation of the tumour and its surrounding tissue, the distribution of physical forces, biochemical niches, cellular neighbourhoods, and the broader tissue and organ context in which the tumour develops. Together, these elements form a dynamic and evolving landscape that is continuously remodelled through the multiscale communication of cellular, biochemical and mechanical components. Understanding the principles that govern these interactions reveals that cancer is not merely a chaotic aggregation of cells, but a patterned system shaped by coordinated spatial relationships. Here, we discuss the recent literature to examine how physical, biochemical and cellular relationships orchestrate tumour initiation, progression and treatment resistance, and how their collaboration acts not as a passive scaffold, but as the architect of tumour behaviour.

  • Open Access

    Neural modulation of ocular immunity: Exploring a sympathetic‐macrophage neuroimmune link in the human ciliary body

    by Tanya S. Karakyriakou, Claire Mackaaij, Mark van Zijverden, Hendrik A. Messal, Jeannette Ossewaarde‐Van Norel, Ronald L. A. W. Bleys, Cindy G. J. Cleypool

    The ciliary body (CB) represents an immunoregulatory compartment for the ocular system and we questioned whether local immune regulation in the CB in humans could be under neural control. In this study, we explored whether the human CB contains a sympathetic‐macrophage neuroimmune link. Seven right eyes from donated cadavers (five male, two female) were enucleated. After removal of the cornea, lens, and vitreous body, each eye was divided into quadrants. One quadrant per eye was processed for light microscopy to assess overall morphology, general and sympathetic nerve presence, varicosities, macrophages, and the proximity of sympathetic nerves to macrophages. Additional quadrants (whole‐mount samples) were examined with three‐dimensional (3D) confocal microscopy to visualize the spatial relationship between sympathetic nerves and macrophages and to determine whether these macrophages expressed β₂‐adrenergic receptors. Our study shows that the human CB contains sympathetic nerves of which a significant amount was spatially associated to β2‐adrenergic receptor expressing macrophages. The current study provides morphological evidence for a possible sympathetic‐macrophage ocular neuroimmune link in humans which may constitute a novel field for the study of degenerative and inflammatory eye disease. Further understanding of the CB sympathetic nerves and their immunomodulatory capacity is needed for the development of future therapeutics.

  • Open Access

    A morphometric signature to identify ductal carcinoma in situ with a low risk of progression

    by Marcelo Sobral-Leite, Simon P. Castillo, Shiva Vonk, Hendrik A. Messal, Xenia Melillo, Noomie Lam, Brandi de Bruijn, Yeman B. Hagos, Myrna van Den Bos, Joyce Sanders, et al.

    Ductal carcinoma in situ (DCIS) may progress to ipsilateral invasive breast cancer (iIBC), but often never will. Because DCIS is treated as early breast cancer, many women with harmless DCIS face overtreatment. To identify features associated with progression, we developed an artificial intelligence-based DCIS morphometric analysis pipeline (AIDmap) on hematoxylin-eosin-stained (H&E) tissue sections. We analyzed 689 digitized H&Es of pure primary DCIS of which 226 were diagnosed with subsequent iIBC and 463 were not. The distribution of 15 duct morphological measurements was summarized in 55 morphometric variables. A ridge regression classifier with cross validation predicted 5-years-free of iIBC with an area-under the curve of 0.67 (95% CI 0.57–0.77). A combined clinical-morphometric signature, characterized by small-sized ducts, a low number of cells and a low DCIS/stroma ratio, was associated with outcome (HR = 0.56; 95% CI 0.28–0.78). AIDmap has potential to identify harmless DCIS that may not need treatment.


  • Open Access

    Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma

    by Aristeidis Papargyriou, Mulham Najajreh, David P. Cook, Carlo H. Maurer, Stefanie Bärthel, Hendrik A. Messal, Sakthi K. Ravichandran, Till Richter, Moritz Knolle, Thomas Metzler, et al.

    In patients with pancreatic ductal adenocarcinoma (PDAC), intratumoural and intertumoural heterogeneity increases chemoresistance and mortality rates. However, such morphological and phenotypic diversities are not typically captured by organoid models of PDAC. Here we show that branched organoids embedded in collagen gels can recapitulate the phenotypic landscape seen in murine and human PDAC, that the pronounced molecular and morphological intratumoural and intertumoural heterogeneity of organoids is governed by defined transcriptional programmes (notably, epithelial-to-mesenchymal plasticity), and that different organoid phenotypes represent distinct tumour-cell states with unique biological features in vivo. We also show that phenotype-specific therapeutic vulnerabilities and modes of treatment-induced phenotype reprogramming can be captured in phenotypic heterogeneity maps. Our methodology and analyses of tumour-cell heterogeneity in PDAC may guide the development of phenotype-targeted treatment strategies.


  • Open Access

    Polytope: High-resolution epitope barcoding for in vivo spatial fate-mapping

    by Daniel Postrach, Colin E. J. Pritchard, Larissa Frank, Tom van Leeuwen, Hendrik A. Messal, Paul Krimpenfort, Jacco van Rheenen, Hans-Reimer Rodewald

    Tracing the fate of individual cells and their progeny remains a challenging task. While imaging-based fate-mapping provides spatial information, it generally lacks complexity due to limited label diversity, resulting in diminished capture of comprehensive lineages and fate maps. Here, we introduce ‘Polytope’, an epitope barcoding system capable of generating up to 512 unique color codes. Comprising nine epitope tag cassettes flanked by loxP sites, Polytope allows random excision via Cre recombinase, creating unique color codes detectable through multiplexed imaging. Using an engineered Polytope mouse, we traced the fate of hundreds of clones across tissues in vivo , from embryonic development until adulthood. Together, Polytope enables high-resolution imaging-based fate-mapping through endogenous epitope barcoding, comprehensively capturing the spatial organization of complex clonal dynamics in situ . One-Sentence Summary: Polytope is an imaging-based barcoding system to trace lineages at clonal and spatial resolution in living organisms using a diverse set of color-coded markers.


  • Open Access

    Mechanisms that clear mutations drive field cancerization in mammary tissue

    by Marta Ciwinska, Hendrik A. Messal, Hristina R. Hristova, Catrin Lutz, Laura Bornes, Theofilos Chalkiadakis, Rolf Harkes, Nathalia S. M. Langedijk, Stefan J. Hutten, Renée X. Menezes, et al.

    Oncogenic mutations are abundant in the tissues of healthy individuals, but rarely form tumours1–3. Yet, the underlying protection mechanisms are largely unknown. To resolve these mechanisms in mouse mammary tissue, we use lineage tracing to map the fate of wild-type and Brca1−/−;Trp53−/− cells, and find that both follow a similar pattern of loss and spread within ducts. Clonal analysis reveals that ducts consist of small repetitive units of self-renewing cells that give rise to short-lived descendants. This offers a first layer of protection as any descendants, including oncogenic mutant cells, are constantly lost, thereby limiting the spread of mutations to a single stem cell-descendant unit. Local tissue remodelling during consecutive oestrous cycles leads to the cooperative and stochastic loss and replacement of self-renewing cells. This process provides a second layer of protection, leading to the elimination of most mutant clones while enabling the minority that by chance survive to expand beyond the stem cell-descendant unit. This leads to fields of mutant cells spanning large parts of the epithelial network, predisposing it for transformation. Eventually, clone expansion becomes restrained by the geometry of the ducts, providing a third layer of protection. Together, these mechanisms act to eliminate most cells that acquire somatic mutations at the expense of driving the accelerated expansion of a minority of cells, which can colonize large areas, leading to field cancerization.


  • Open Access

    Rat Models of Hormone Receptor-Positive Breast Cancer

    by Raquel Nicotra, Catrin Lutz, Hendrik A. Messal, Jos Jonkers

    Hormone receptor-positive (HR+) breast cancer (BC) is the most common type of breast cancer among women worldwide, accounting for 70–80% of all invasive cases. Patients with HR+ BC are commonly treated with endocrine therapy, but intrinsic or acquired resistance is a frequent problem, making HR+ BC a focal point of intense research. Despite this, the malignancy still lacks adequate in vitro and in vivo models for the study of its initiation and progression as well as response and resistance to endocrine therapy. No mouse models that fully mimic the human disease are available, however rat mammary tumor models pose a promising alternative to overcome this limitation. Compared to mice, rats are more similar to humans in terms of mammary gland architecture, ductal origin of neoplastic lesions and hormone dependency status. Moreover, rats can develop spontaneous or induced mammary tumors that resemble human HR+ BC. To date, six different types of rat models of HR+ BC have been established. These include the spontaneous, carcinogen-induced, transplantation, hormone-induced, radiation-induced and genetically engineered rat mammary tumor models. Each model has distinct advantages, disadvantages and utility for studying HR+ BC. This review provides a comprehensive overview of all published models to date.


  • Open Access

    Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts

    by Stefan J Hutten, Hendrik A Messal, Esther H Lips, Michael Sheinman, Marta Ciwinska, Esmee Braams, Carolien van der Borden, Petra Kristel, Saskia Stoffers, Lodewyk Fa Wessels, et al.

    Mutations are abundantly present in tissues of healthy individuals, including the breast epithelium. Yet it remains unknown whether mutant cells directly induce lesion formation or first spread, leading to a field of mutant cells that is predisposed towards lesion formation. To study the clonal and spatial relationships between morphologically normal breast epithelium adjacent to pre‐cancerous lesions, we developed a three‐dimensional (3D) imaging pipeline combined with spatially resolved genomics on archival, formalin‐fixed breast tissue with the non‐obligate breast cancer precursor ductal carcinoma in situ (DCIS). Using this 3D image‐guided characterization method, we built high‐resolution spatial maps of DNA copy number aberration (CNA) profiles within the DCIS lesion and the surrounding normal mammary ducts. We show that the local heterogeneity within a DCIS lesion is limited. However, by mapping the CNA profiles back onto the 3D reconstructed ductal subtree, we find that in eight out of 16 cases the healthy epithelium adjacent to the DCIS lesions has overlapping structural variations with the CNA profile of the DCIS. Together, our study indicates that pre‐malignant breast transformations frequently develop within mutant clonal fields of morphologically normal‐looking ducts. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.


  • Open Access

    BCRP drives intrinsic chemoresistance in chemotherapy-naïve breast cancer brain metastasis

    by Rebeca Uceda-Castro, Andreia S. Margarido, Ji-Ying Song, Mark C. de Gooijer, Hendrik A. Messal, Cecilia R. Chambers, Max Nobis, Ceren H. Çitirikkaya, Kerstin Hahn, Danielle Seinstra, et al.

    Although initially successful, treatments with chemotherapy often fail because of the recurrence of chemoresistant metastases. Since these tumors develop after treatment, resistance is generally thought to occur in response to chemotherapy. However, alternative mechanisms of intrinsic chemoresistance in the chemotherapy-naïve setting may exist but remain poorly understood. Here, we study drug-naïve murine breast cancer brain metastases (BCBMs) to identify how cancer cells growing in a secondary site can acquire intrinsic chemoresistance without cytotoxic agent exposure. We demonstrate that drug-naïve murine breast cancer cells that form cancer lesions in the brain undergo vascular mimicry and concomitantly express the adenosine 5′-triphosphate–binding cassette transporter breast cancer resistance protein (BCRP), a common marker of brain endothelial cells. We reveal that expression of BCRP by the BCBM tumor cells protects them against doxorubicin and topotecan. We conclude that BCRP overexpression can cause intrinsic chemoresistance in cancer cells growing in metastatic sites without prior chemotherapy exposure.